The results of a phase 2b proof-of-concept study of 889 HIV-negative women in KwaZulu-Natal, South Africa, have shown that a gel for vaginal application containing 1% of the antiretroviral drug tenofovir is safe and effective for preventing HIV. Antiretroviral drugs have been shown to effectively treat people living with HIV, and to prevent mother-to-child transmission, but this is the first time an antiretroviral gel has been shown to prevent sexually transmitted HIV.
展开▼
